Advanced Enzyme Technologies Ltd

- There is no mention of any current or planned fundraising through debt or equity in the discussion. - On CapEx, the company plans for potential greenfield or brownfield expansion around FY28-29 with estimated costs of about INR 50 crore. - CapEx for the current year is limited to R&D Center-related expenses only. - The company focuses on internal growth, R&D investments, and capacity utilization without indicating external fundraising. - Board considerations such as buybacks are probabilistic and not confirmed, with no concrete plans announced.

- No major CapEx planned for the current fiscal year except for R&D-related investments. - Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year. - Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation. - Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion. - Continued efforts to invest in R&D and new product pipelines to support growth and market expansion. - Strategic investments linked to evolving market opportunities such as healthcare, biochemical processing, and industrial enzymes.

- The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19). - The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17). - U.S. sales volumes are expected to pick up within the current financial year, aided by improved tariff conditions and increased inquiries (Pages 19, 21). - R&D and new product launches will support sustained growth (Pages 17, 19).

- The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years. - Growth will be uneven ("roller coaster"), with some years faster and some slower. - EBITDA margins may face tariff impacts, but current outlook suggests a worst-case 1% impact (vs. earlier 2%), with efforts to pass costs to customers to mitigate margin pressure. - Profit before tax and profit after tax have shown increases in recent quarters, reflecting improving financials. - Expansion of product pipelines, including enzymes, probiotics, biocatalysis, and biopharma areas, is expected to drive future top-line growth. - New R&D centers and innovations are expected to support growth in new applications and market areas, especially healthcare and biochemical processing. - U.S. market performance is critical and improving, aided by lower tariffs and strategic customer management, which should enhance earnings going forward.

- Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year. - The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes. - There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders. - No explicit details on the exact size or value of the current order book or pending orders were provided in the call. - Management emphasizes a pipeline-driven approach rather than reliance on single-product orders, aiming for steady revenue generation as products mature. - The outlook includes increased inquiries and interest reflecting a healthier order flow expected in the near to medium term.